High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

BACKGROUND Insulin-like growth factor receptor-1 (IGFR-1) represents a novel molecular target in non-small-cell lung cancer (NSCLC). IGFR-1 and epidermal growth factor receptor (EGFR) activation is essential to mediate tumor cell survival, proliferation and invasion. We explored the correlation between IGFR-1 and EGFR, their relationship with clinicopathological parameters and their impact on outcome in resected stage I-III NSCLC patients. PATIENTS AND METHODS Tumors from 125 surgical NSCLC patients were evaluated for IGFR-1 and EGFR expression by immunohistochemistry. Kaplan-Meier estimates of survival and time to recurrence were calculated for clinical variables and biologic markers using the Cox model for multivariate analysis. RESULTS IGFR-1 protein overexpression was detected in 36.0% of NSCLC patients and was associated with larger tumor size (P = 0.04) but not with other clinical or biological characteristics. EGFR protein overexpression was observed in 55.2% of NSCLC, more frequently in squamous cell carcinoma (SCC) than non-SCC (63.7% versus 36.3%, chi(2) = 9.8, P = 0.001). IGFR-1 protein expression was associated with EGFR protein expression (P = 0.03). At the multivariate analysis, high coexpression of both IGFR-1 and EGFR was a significant prognostic factor of worse disease-free survival (DFS) (hazard ratio 2.51, P = 0.01). CONCLUSION A statistically significant association was observed between high coexpression of both IGFR-1 and EGFR and worse DFS in early NSCLC patients.

[1]  G. Gibson,et al.  Epidermal growth factor receptors in non-small cell lung cancer. , 1987, British Journal of Cancer.

[2]  C. Angeletti,et al.  Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  S. Hilsenbeck,et al.  Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[5]  Arnab Chakravarti,et al.  Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. , 2002, Cancer research.

[6]  K. Wester,et al.  HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer. , 2004, Acta oncologica.

[7]  M. Rubini,et al.  The IGF-I receptor in cell growth, transformation and apoptosis. , 1997, Biochimica et biophysica acta.

[8]  F. Cappuzzo,et al.  Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Korsmeyer,et al.  Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor* , 2002, The Journal of Biological Chemistry.

[10]  M Paesmans,et al.  The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis , 2002, European Respiratory Journal.

[11]  A. Marchevsky.  Classification of lung tumors , 1990 .

[12]  N. Reinmuth,et al.  Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. , 2000, The European respiratory journal.

[13]  Adrian V. Lee,et al.  Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  R. Nicholson,et al.  Growth factor receptor interplay and resistance in cancer. , 2006, Endocrine-related cancer.

[15]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Volm,et al.  Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas , 2005, Journal of Cancer Research and Clinical Oncology.

[17]  K. Kikuchi,et al.  Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. , 2000, Oncology reports.

[18]  R. Baserga.  The IGF-I receptor in cancer research. , 1999, Experimental cell research.

[19]  E. Dmitrovsky,et al.  Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[21]  Domenico Coppola,et al.  Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. , 2003, Human pathology.

[22]  D. Leroith,et al.  Role of the IGF-I receptor in mutagenesis and tumor promotion. , 1997, Journal of Endocrinology.

[23]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[24]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[25]  Elisabeth Brambilla,et al.  The 2004 World Health Organization classification of lung tumors. , 2005, Seminars in roentgenology.

[26]  A. Hölscher,et al.  Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  G Nilsson,et al.  Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. , 1999, Cancer research.

[28]  B. van der Burg,et al.  Mitogenic Signaling of Insulin-like Growth Factor I in MCF-7 Human Breast Cancer Cells Requires Phosphatidylinositol 3-Kinase and Is Independent of Mitogen-activated Protein Kinase* , 1997, The Journal of Biological Chemistry.

[29]  P. Glazer,et al.  Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. , 1997, Cancer research.

[30]  L. Kołodziejski,et al.  EGFR LI and Ki-67 LI are independent prognostic parameters influencing survivals of surgically treated squamous cell lung cancer patients. , 2005, Neoplasma.

[31]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[32]  S. Novello,et al.  High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC , 2008 .

[33]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[34]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[35]  V Torri,et al.  Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  F. Hirsch,et al.  High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts) , 2007 .

[37]  D. Cox.  Regression Models and Life-Tables , 1972 .

[38]  W. Travis,et al.  The new World Health Organization classification of lung tumours , 2001, European Respiratory Journal.

[39]  M. Buyse,et al.  Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.